These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
4. Management of high-risk non-muscle invasive bladder cancer. Brausi M; Olaru V Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212 [TBL] [Abstract][Full Text] [Related]
5. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. Herr HW J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743 [TBL] [Abstract][Full Text] [Related]
6. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. Krege S; Giani G; Meyer R; Otto T; Rübben H J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374 [TBL] [Abstract][Full Text] [Related]
7. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate. Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246 [TBL] [Abstract][Full Text] [Related]
8. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence]. Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813 [TBL] [Abstract][Full Text] [Related]
9. Guidelines on diagnosis and treatment of superficial bladder cancer. Oosterlinck W Minerva Urol Nefrol; 2004 Mar; 56(1):65-72. PubMed ID: 15195031 [TBL] [Abstract][Full Text] [Related]
12. BCG and the treatment of superficial bladder cancer. Moss JT; Kadmon D DICP; 1991 Dec; 25(12):1355-67. PubMed ID: 1815434 [TBL] [Abstract][Full Text] [Related]
13. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422 [TBL] [Abstract][Full Text] [Related]
14. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
15. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
16. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637 [TBL] [Abstract][Full Text] [Related]
19. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147 [TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]